A possible serologic biomarker for maternal immune activation-associated neurodevelopmental disorders found in the rat models  by Oh-Nishi, Arata et al.
A
a
t
A
a
T
b
c
a
A
R
R
A
A
K
M
S
I
S
A
N
1
m
t
s
i
P
I
c
I
c
T
f
M
J
h
0
nNeuroscience Research 113 (2016) 63–70
Contents lists available at ScienceDirect
Neuroscience  Research
jo ur nal homepage: www.elsev ier .com/ locate /neures
 possible  serologic  biomarker  for  maternal  immune
ctivation-associated  neurodevelopmental  disorders  found  in
he  rat  models
rata  Oh-Nishia,∗,1, Kaori  Kogab, Tadakazu  Maedac, Tetsuya  Suharaa
Department of Functional Brain Imaging, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Sciences and
echnology, Chiba 263-8555, Japan
Anatech Corporation, Tokyo 113-0034, Japan
Professor Emeritus, Kitasato University, Kanagawa 252-0373, Japan
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 9 February 2016
eceived in revised form 21 June 2016
ccepted 7 July 2016
vailable online 15 July 2016
eywords:
aternal immune activation
erologic biomarker
g  light chain
a  b  s  t  r  a  c  t
Epidemiological  studies  have  shown  that  maternal  infection  during  early  pregnancy  increases  the
risk  of neurodevelopmental  disorders  (i.e.,  schizophrenia  or  autism)  in  offspring.  Recently,  diag-
nostic/stratiﬁcation  biomarkers  for  the  maternal  immune  activation  background  in patients  with
neurodevelopmental  disorders  have  been  energetically  searched  for  in  the  patient  blood.  Here,  we  report
a novel  serologic  marker  candidate  for  the  disorders  found  in  the  maternal  immune  activation  (MIA) rat
model. Serum  proteome  analysis  of the  MIA rat showed  that  the  immunoglobulin  (Ig)  light  chain  is repro-
ducibly  augmented.  The  Ig light  chain  in sera  takes  two forms  —  free  form  or bound  to  the  Ig heavy  chain.
Only  the  former  is an inﬂammatory  disease  marker,  but  pro-inﬂammatory  cytokine  levels  in  the  sera  of
the MIA  rats  were  below  detectable  limits  of  the  ELISA  protocol  we  used.  We  thereby  carried  out  serumchizophrenia
utism
eurodevelopmental disorders
assays  of  Ig light  chains  and  pro-inﬂammatory  cytokines  of  commercially  available  schizophrenia  patient
sera for  research.  Although  the  number  of samples  was  limited,  we  found  augmentation  of  free  Ig light
chains but  not  pro-inﬂammatory  cytokines  in sporadic  schizophrenia  patient  sera.  Our  ﬁndings  suggest
that  Ig  light chain  assay  of  the schizophrenia/autism  patient  sera  would  be worthy  to  be validated  in
larger  scale.
©  2016  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an open  access  article  under  the CC. Introduction
Emerging literature has provided epidemiological evidence that
aternal immune activation (MIA) during the ﬁrst half of gesta-ion increases the risks of neurodevelopmental disorders including
chizophrenia and autism in offspring, based on the fact that these
ncreased risks are correlated not only with inﬂuenza infection at
Abbreviations: MIA, maternal immune activation; Ig, immunoglobulin;
oly  I:C, synthetic polyriboinosinic-polyribocytidilic acid; GD, gestation day;
.P.,  intraperitoneally; 2-DE, two-dimensional electrophoresis; CHAPS, 3-((3-
holamidopropyl)dimethylammonium)-1-propanesulfonate; DTT, dithiothreitol;
PG, immobilized pH gradient; BPB, bromophenol blue; KLH, keyhole-limpet hemo-
yanin; HRP, horseradish-peroxidase; IL-6, interleukin 6; IL-1, interleukin 1;
NF-,  tumor necrosis factor ; FLC, free immunoglobulin  light chain; FLC,
ree  immunoglobulin  light chain; FLCs, free Ig light chains; rFLC, -to- FLC ratio;
HC, major histocompatibility complex.
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168-0102/© 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access
c-nd/4.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
pregnancy (Barr et al., 1990; Brown et al., 2004; Kendell and Kemp,
1989) but also with other maternal infectious diseases (Blomstrom
et al., 2012; Brown and Susser, 2002; Lee et al., 2015; Suvisaari et al.,
1999) such as poliovirus,  rubella and T. gondii.  From this, we can infer
that not a speciﬁc viral infection but MIA  itself would increase the
risks in offspring. It is estimated that 30% of schizophrenia cases
could be prevented if certain prenatal infections were entirely elim-
inated from the pregnant population (Brown and Derkits, 2010;
Cannon et al., 2014). MIA  would be a common immune-related
background for neurodevelopmental disorders in offspring. In fact,
a number of studies have been published that searched for clues to
diagnostic/stratiﬁcation biomarkers of such disorders (Blomstrom
et al., 2015; Tomasik et al., 2012; Vargas, 2014), but candidates
for related diseases with immune-related background have not yet
been fully found.
MIA  of pregnant rodents can be induced by injection of synthetic
polyriboinosinic-polyribocytidilic acid (Poly I:C), which mimics
viral infections through Toll-like receptor 3 stimulation and causes
their offspring to have permanent immune system disturbances
and behavioral abnormalities (Hsiao et al., 2012, 2013; Meyer,
 article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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013a,b; Meyer et al., 2005; Patterson, 2009). A non-human pri-
ate Poly I:C complex-induced MIA  model has also presented
lteration of social attention, abnormal behavioral development
nd neuropathology (Bauman et al., 2014; Machado et al., 2015;
eir et al., 2015). Although the total picture of the MIA  model
nimal phenotype has still to be fully clariﬁed, we herein suggest
ts usefulness in our quest for diagnostic/stratiﬁcation markers of
IA-associated neurodevelopmental disorders.
In the present study, we explored a novel serologic MIA-
ssociated marker candidates in the serum proteome of the rat
odel. To see whether we can ﬁnd corresponding markers in
uman samples, we carried out a pilot study using sporadic
chizophrenia patient sera for research.
. Materials and methods
.1. Experimental animal care
All experiments were performed in accordance with interna-
ional guidelines on the ethical use of animals (NIH Guide for the
are and Use of Laboratory Animals) and the guidelines of the
ational Institute of Radiological Sciences in Chiba, Japan, and all
fforts were made to minimize suffering and the number of ani-
als used. The present study was approved by the Animal Ethics
ommittee of the National Institute of Radiological Sciences, Chiba,
apan. The rats were housed under controlled temperature and at
 12-h light/dark cycle with food and water ad libitum until the
xperiments.
.2. Preparation of MIA  rat
Female Wistar rats (Japan SLC, Shizuoka, Japan) were mated at
2–15 weeks of age. The ﬁrst day after copulation was  deﬁned
s gestation day 1 (GD1). Poly I:C potassium salt (Product No.
9582, Lot No. 012M4032V, Sigma–Aldrich, Tokyo, Japan) (4 mg/kg)
issolved in saline was injected into the pregnant Wistar rats
ntraperitoneally (I.P.) daily for 4 consecutive days from GD15 to
D18. Their neonatal- or mature-male offspring (postnatal days 3
r postnatal weeks 9–16) were used as MIA  rats. We  also injected
aline (vehicle) into pregnant Wistar rats by the same procedures
nd their male offspring were used as controls. In the present study,
ll pregnant Wistar rats having been injected with Poly I:C potas-
ium salt or with only saline could give birth to living pups (Poly
C treated dams: N = 9 and saline treated dams: N = 7). The num-
er of offspring per dam were not signiﬁcantly different between
he two groups of dams (Poly I:C treated dam: 9 ± 1.11 and saline
reated dam 9.5 ± 0.75 (mean ± SEM), t(14) = 0.39, P = 0.69 (Stu-
ent’s t-test)). All offspring were culled to 6–8 pups on postnatal
ay 3. Offspring were separated from their mothers 21 days after
irth. We  prepared 1–3 male offspring from each dam for each
erum analyses.
.3. Antipsychotic drug injection
The MIA  rats (9 weeks postnatal) were injected intramuscu-
arly (I.M.) with haldol-decanoate (Sumitomo Dainippon Pharma,
okyo, Japan) (0.5 mg/kg) or propylene glycol (Vehicle) (Vincent
t al., 1994). Sera were collected 3 weeks later.
.4. Rat serum samplingBlood was collected from deeply anesthetized rats with an
verdose of pentobarbital (Kyoritsu Seiyaku Co., Tokyo, Japan)
y cardiac puncture with 23-gauge needles attached to 2.5 ml
yringes. Blood was incubated for 3 h at 4 ◦C and centrifuged foresearch 113 (2016) 63–70
40 min  at 1000 × g at 4 ◦C. Supernatant sera were collected and
stored at −80 ◦C until use.
2.5. Two-dimensional electrophoresis (2-DE) and image analysis
We  carried out standard 2-DE as described previously (Koga
and Minohata, 2011). An aliquot of a serum sample was mixed
at a volume ratio of 1:1 with an extraction medium (7 M urea,
2 M thiourea, 2% 3-((3-cholamidopropyl)dimethylammonium)-1-
propanesulfonate (CHAPS), 0.1 M dithiothreitol (DTT), and 2.5%
Pharmalyte (pH 3–10)), and was homogenized using an ultrasonic
disruptor (UR-20P; Tomy Seiko, Tokyo, Japan), followed by 20-min
centrifugation at 15,000 rpm, 4 ◦C, using Centrifuge 3500 (Kubota,
Gunma, Japan). The supernatant was collected and stored at −80 ◦C
until use. An 18-cm-long dry immobilized pH gradient (IPG) gel
strip (GE Healthcare, Tokyo, Japan) was rehydrated for 8–24 h at
20 ◦C in rehydration buffer (7 M urea, 2 M thiourea, 2% triton X-
100, 13 mM DTT, 1% Pharmalyte (pH 3–10), 25 mM  acetic acid, and
0.025% bromophenol blue (BPB)). The sample solution (0.054 ml)
was applied to ﬁlter paper, which was  placed on the cathodic edge
of an immobilized pH gradient (IPG) gel strip. IPG gel strips were
subjected to 1st dimension isoelectric focusing (IEF) electrophore-
sis in CoolPhoreStar IPG IEF Type PX (Anatech, Tokyo, Japan). After
the 1st dimension IEF, the IPG gel strips were rinsed brieﬂy in dis-
tilled water to remove silicon oil and were then equilibrated for
40 min  at room temperature under gentle shaking in SDS treat-
ment buffer (6 M urea, 32.5 mM DTT, 25% glycerol, 25 mM Tris–HCl
(pH 6.8), 0.0025% BPB, and 2% SDS). The IPG gel strips were then
placed on top of 12% SDS-polyacrylamide slab gels for 2nd dimen-
sion SDS-PAGE.
The 2nd dimension SDS-PAGE was carried out with
CoolPhoreStar SDS-PAGE Dual 200 K (Anatech), after which
the slab gels were stained with Flamingo ﬂuorescent gel stain
(Bio-Rad). FluoroPhoreStar 3000 (Anatech) was used for capturing
ﬂuorescent images of the Flamingo-stained slab gels. These ﬂuores-
cent images were captured three times per gel, and were analyzed
by Progenesis PG220 (Nonlinear Dynamics, Newcastle-upon-Tyne,
UK). The integrated ﬂuorescent intensity of a spot in a gel image
was calculated after subtracting the lowest-on-boundary pixel
intensity around the spot from the pixel intensity within the spot.
2.6. Identiﬁcation of proteins by LC–MS/MS
We  identiﬁed proteins in 2-DE gels by following a standard
protocol with several modiﬁcations (Shevchenko et al., 2006).
Flamingo-stained spots were excised from a 2-DE slab gel using Flu-
oroPhoreStar3000 (Anatech). Excised gel pieces were submitted for
protein identiﬁcation by mass spectrometry, which were processed
using a robot (ProGest, DigiLab, MA,  USA) by the following protocol:
the gel pieces were washed with 25 mM ammonium bicarbonate
followed by acetonitrile, reduced with 10 mM DTT at 60 ◦C followed
by alkylation with 50 mM 2-iodoacetamide at room temperature,
and trypsin digestion (Promega) at 37 ◦C for 4 h. Finally, the samples
were quenched with formic acid and the supernatant containing
digested peptides was used for protein identiﬁcation by mass-
spectrometry without further processing. The experiments were
performed by RelyOn Ltd. (Tokyo, Japan).
Our nano LC/MS/MS system was equipped with a Waters
NanoAcquity HPLC system (Waters Corp., MA,  USA) interfaced to
a ThermoFisher Orbitrap Velos Pro (Thermo Fisher Scientiﬁc K.K.,
Kanagawa, Japan). Peptides were loaded on a trapping column of
the nano LC and eluted over a 75-m-diameter nano LC column at
a ﬂow rate of 350 nL/min; both columns were packed with Jupiter
Proteo resin (Phenomenex, CA, USA). The mass spectrometer was
operated in data-dependent mode, with MS  performed in the Orbit-
rap at 60,000 FWHM resolution and MS/MS  performed in LTQTM
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Thermo Fisher Scientiﬁc K.K.). The 15 most abundant ions were
elected for MS/MS. The nano LC–MS/MS experiments were per-
ormed by RelyOn Ltd.
Database search concerning MS/MS  peptide data was carried
ut at Uniprot DB (http://www.uniprot.org/) by using Mascot, a
ass spectrum analysis software. The Mascot program was  given
atabase query arguments as follows. Enzyme: Trypsin, Database:
niprot Rat (concatenated forward and reverse plus common con-
aminants), Fixed modiﬁcation: Carbamidomethyl (C), Variable
odiﬁcations: Oxidation (M), Acetyl (Protein N-term), Deamida-
ion (NQ), Pyro Glu (N-term Q), Mass values: Monoisotopic, Peptide
ass Tolerance: 10 ppm, Fragment Mass Tolerance: 0.8 Da, Max
issed Cleavages: 2. Mascot DAT ﬁles obtained by the database
uery were parsed by Scaffold, a MS/MS  data validation software
or creating a non-redundant peptide list (Proteome Software, Inc.,
R, USA). Database query results were ﬁltered using a minimum
rotein value of 90%, a minimum peptide value of 50% in Prophet
cores, and at least two unique peptides were required for suc-
essful identiﬁcation of a protein. The LC–MS/MS identiﬁcation of
roteins explained above was done by RelyOn Ltd.
.7. Western blotting using anti-rat immunoglobulin  (Ig-)
ight chain antibody
We  prepared polyclonal rabbit anti-rat Ig- light chain
ntibodies using an immunizing peptide conjugated with the
eyhole-limpet hemocyanin (KLH) protein. The immunizing pep-
ide had a partial sequence from the 54th to the 73rd amino acid
f rat Ig- (SVTDQDSKDSTYSMSSTLSL) (Sheppard and Gutman,
981) plus a cysteine residue at the N terminus where KLH was
onjugated. Two rabbits were immunized twice by subcutaneous
njections of 4 mg  of the peptide. Crude antisera of both rabbits
ere afﬁnity-puriﬁed against the immobilized immunizing pep-
ide. Preparation and puriﬁcation of the polyclonal rabbit anti-rat
g- antibodies were performed by RESVO Inc., Tokyo, Japan. The
peciﬁcity of anti-sera was conﬁrmed by dot blot.
Sera of the control and MIA  rats were respectively mixed at a
olume ratio of 1:1 with protein extracting buffer solutions includ-
ng 100 mM Tris–HCl, pH 8.8, 2% SDS, 20% sucrose, 0.06% BPB, 7 M
rea, 2 M thiourea and 0.1 M DTT. The mixture was  subjected to
0–20% gradient SDS-PAGE (ATTO, Tokyo Japan). Electrophoresed
roteins were transferred from the SDS-PAGE gel to a PVDF mem-
rane (ATTO), which was blocked for 1 h at room temperature in
zBlock BSA (ATTO), a blocking buffer solution. The PVDF mem-
rane was then incubated overnight at 4 ◦C in a blocking buffer
olution containing 1:1000-diluted rabbit anti-rat Ig- light chain
rimary antibody or 1:20,000-diluted rabbit anti-rat albumin pri-
ary antibody (Assaypro, MO,  USA) and ﬁnally transferred into a
locking buffer solution containing a horseradish-peroxidase (HRP)
onjugated anti-rabbit IgG (GE Healthcare). Chemiluminescence
rom HRP elicited by ImmunoStar Zeta or ImmunoStar Basic (Wako,
okyo, Japan) was detected by ChemiDoc XRS.
Optical density (OD) of protein bands was determined by using
mage J (NIH, Bethesda, MD,  USA), followed by normalization to
he albumin OD for correcting variations in loading. Finally, the OD
atio values were scaled to the average values of the control rats.
.8. Measurement of cytokines in serum of ratRat serum Interleukin 6 (IL-6) concentration was  measured by
at IL-6 colorimetric ELISA kit (Thermo Scientiﬁc, IL, USA), and rat
umor Necrosis Factor  (TNF-)  and Interleukin 1 (IL-1) by
uantikine® ELISA kits (R&D Systems Inc., MN,  USA).esearch 113 (2016) 63–70 65
2.9. Human sera sample
Anonymized sera of sporadic schizophrenia patients and
healthy controls were purchased from PrecisionMed. Inc. (CA, USA;
see details at http://www.precisionmed.com/) and stored at −80 ◦C
until use. The present human sample study was approved by clin-
ical ethics committees of the National Institute of Radiological
Sciences, Chiba, Japan. Free Ig- light chain (FLC) and free Ig-
 light chain (FLC) (FLC isoform) production are augmented
under chronic inﬂammatory diseases (van der Heijden et al., 2006)
and clonal diseases (Katzmann et al., 2002; Kuku et al., 2005;
Tsirakis et al., 2011). To exclude false-positive or -negative donors,
we ﬁrst inspected anonymized medical charts of those donors
supplied by PrecisionMed. Inc. in terms of whether their clini-
cal data satisﬁed the following conditions: (1) Donors must be
free of medical diseases. (2) The pro-inﬂammatory cytokine con-
centrations in serum samples must be below the ELISA detection
limits (IL-6 < 10 pg/ml; IL-1 < 3 pg/ml; TNF- < 10 pg/ml). (3) To
exclude donors with clonal diseases such as myeloma, the -to-
 ratio values in sera samples must be within the reference range
(0.26–1.65) (Katzmann et al., 2002). (4) The mean ages of the two
groups must match closely. (5) Finally, the gender of donors was
limited to males. The numbers of sera samples that satisﬁed the
selection criteria were 8 patients (mean age 43.8 ± 3.5 y.o., dura-
tion of illness 23.2 ± 3.3 years, PANSS positive score 17.8 ± 1.8,
negative score 16.7 ± 1.5, general score 37.5 ± 3.3, chlorpromazine
equivalent antipsychotic dose 995.7 ± 262.2 mg/day) and 9 healthy
controls. We  measured FLCs in sera samples of the patients with
sporadic schizophrenia (N = 8) and healthy control (N = 9) donors
purchased from PrecisionMed, Inc., USA.
2.10. Measurement of free immunoglobulin  light chain (FLC)
and free immunoglobulin  light chain (FLC) in human sera
FLC and FLC in human sera were measured using Freelight
® and Freelight ® (The Binding Site, Burmingham, UK). The mea-
surements were done by LSI Medience Co., Ltd.
2.11. Data analysis and statistical analysis
All results were expressed as mean ± SD. Comparisons of the
two groups were performed by multiple t-test, two-tailed Student’s
t-test or Mann–Whitney U-test. In all cases, differences were con-
sidered signiﬁcant when P < 0.05. As the number of samples was
limited, we  carried out power analysis using G* power, a free sta-
tistical analysis software package available for OS X and Windows
(see details at http://www.gpower.hhu.de/).
3. Results
3.1. Exploration for serum markers in the MIA  rat
We used standard methods of proteomics to search for serum
biomarkers in the mature MIA  rat (postnatal weeks 16). First, we
separated serum proteins of the MIA  and control rats individually
by 2-DE, followed by comparison of the 2-DE patterns between
the MIA  model and control samples (N = 3 each). Using Progen-
esis PG220 (Nonlinear Dynamics, Newcastle-upon-Tyne, UK), we
matched 482 spot images with each other in the 2-DE patterns of
the MIA  and the control samples (Supplementary Fig. 1). Among
the 482 spots in the 2-DE images, 3 spots showed difference in vol-
ume  between MIA  and control samples with uncollected P value
of less than 0.01, although any of the differences did not reach
signiﬁcance after adjusting for multiple comparisons. The sum-
mary statistics for the 3 spots were as follows: Spot 1: t(4) = 25.98,
P = 0.006 (uncorrected), effect size = 4.16,  ˛ error probability: 0.05,
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ower (1−ˇ  error probability): 0.99, and the volume ratio of the
pots in 2-DE images of the 6 MIA:control pairs: 4.04; Spot 2:
(4) = 6.32, P = 0.003 (uncorrected), effect size = 5.17,  ˛ error proba-
ility: 0.05, Power (1−  ˇ error probability): 0.999, and the volume
atio of the spots in 2-DE images of the 6 MIA:control pairs: 2.18;
pot 3: t(4) = −12.77, P = 0.0002 (uncorrected), effect size = 10.43,
 error probability: 0.05, Power (1−  ˇ error probability): 1, and the
olume ratio of the spots in 2-DE images of the 6 MIA:control pairs:
.5. Although protein extractions from spots 2 and 3 (Supplemen-
ary Fig. 1B) were failed probably due to insufﬁcient amount of
roteins, proteins from spot 1 (Fig. 1A) was successfully extracted
nd subjected to the LC–MS/MS protein identiﬁcation.
ig. 1. Serum proteome analysis of mature MIA rat (postnatal weeks 16). (A) Locally
xpanded 2-DE patterns in the vicinities of spot 1 in each of the three control and
hree MIA model rat sera. Red arrows in the panels indicate the spots chosen as
arker candidates. Green lines in the panels indicate spot boundaries. (B) Mascot
core distribution by MS/MS  identiﬁcation of the protein extracted from the candi-
ate 2-DE spots surrounded by the green lines in (A). As Mascot scores higher than
7  are considered signiﬁcant, we considered the top-ranked protein with a Mascot
core of 122 in (B) to be the Ig- chain C region.esearch 113 (2016) 63–70
We  identiﬁed the protein in the spot by the following procedure:
excision of the 2-DE spot, in-gel trypsin digestion of the protein in
the spot, separation of peptides of the digested protein by liquid
chromatography, and peptide identiﬁcation by tandem mass spec-
trometry (LC–MS/MS). As shown in Fig. 1B, the top-ranked peptide
identiﬁed by Mascot search was the Ig- light chain C region, a con-
stitutive part of the Ig- light chain. The apparent molecular mass
of the protein spot estimated from electrophoretic mobility in the
2-DE gel was approximately 25k, also conforming to the reported
molecular mass of 22.5k of the Ig- light chain (Davies et al., 1975).
The rabbit anti-rat Ig- light chain antibody was  produced in
our laboratory by immunizing a rabbit with a synthetic peptide
representing an amino acid sequence (54–73) of rat Ig- light chain.
Fig. 2A shows an example Western blotting image of SDS-PAGE of
a control rat serum using the polyclonal anti-rat Ig- light chain
antibody. The antibody stained a single band in SDS-PAGE gel at
about 25k. Upper panels in Fig. 2B are example Western blotting
patterns that compare the MIA  and control sera Ig- of mature rats
(postnatal weeks 16) using the antibody. Western blotting images
were quantiﬁed by Image-J and normalized by the albumin levels,
followed by scaling to the mean of the control sera. Filled and open
dots in the lower panel of Fig. 2B are Ig- light chain levels of the
MIA  (ﬁlled dots) and control sera (open dots), respectively. The Ig-
light chain level in the sera of the mature MIA  rats was  about 2.1
times as high as that of the control one (t(12) = 3.52, P = 0.004, N = 7
each, Fig. 2B). Similarly to Fig. 2B, Fig. 2C shows neonatal rat data;
example Western blotting patterns are in the upper panel and dot
charts in the lower graph, showing that the serum Ig- light chain
level in neonatal MIA  rat (postnatal days 3) was  about 1.6 times as
high as that of the control rats (t(10) = 5.791, P = 0.0005, N = 6 each,
Fig. 2C).
Augmentation of Ig- light chain in the serum is a result of B-
cell activation (Davies et al., 1975). We therefore conjectured that
augmentation of Ig- light chain in mature MIA rat sera would pre-
sumably be a result of B lymphocyte cell activation. Free Ig-light
chains (FLCs) including Ig- light chain in sera are chronic inﬂam-
mation markers (van der Heijden et al., 2006), but in the sera of
mature MIA  rats (N = 7) three pro-inﬂammatory cytokines, IL-1,
IL-6 and TNF-, were all undetectable with ELISA detection limits
of 62.5 pg/ml, 62.5 pg/ml and 25 pg/ml, respectively.
We  investigated the effect of antipsychotic drug (haloperidol-
decanoate) long-acting injection on Ig- light chain in sera of the
MIA  rat by Western blotting. The Ig- light chain bands of the
haloperidol-decanoate-injected MIA  rat sera were not signiﬁcantly
different (data now shown) in staining intensities from the vehicle-
injected sera (t(8) = 0.51, P = 0.61, N = 5 each).
Our rat model study showed augmentation of Ig- light chains
but not of the three pro-inﬂammatory cytokines, IL-6, IL-1 and
TNF-, in mature MIA  rat sera. These ﬁndings suggest that the
augmentation of Ig- light chain was  caused by immune B-cell
activation in the rat, accompanied by elevation of polyclonal FLCs.
3.2. Free Ig light chains (FLC) in sporadic schizophrenia patient
sera — a pilot study
Protein syntheses of Ig heavy and light chains in mammalian
immune systems are asynchronously carried out on different ribo-
somes in immune B cells, Ig light chain production is 10% to 40%
higher than Ig heavy chain production, and excess light chains are
secreted as free Ig light chains (FLCs) into the blood stream of the
host (Nakano et al., 2011). Two isoforms of Ig light chains, Ig-  and
Ig- light chains, are produced in the human immune system, and
the -to- ratio (rFLC) of the two  light chains is species-dependent
(Redegeld and Nijkamp, 2003; Redegeld et al., 2002).
If B-cell activation, found in the serum proteome of the MIA
model rat, also takes place in patients with schizophrenia, it would
A. Oh-Nishi et al. / Neuroscience Research 113 (2016) 63–70 67
Fig. 2. Serum Ig- light chain Western blot analysis of MIA  rat. (A) An example Western blotting image of a control rat serum using polyclonal rabbit anti-rat Ig- antibody.
The  antibody stained a single band at about 25k. (B) Serum Ig- light chain Western blot analysis of mature MIA  rat (postnatal weeks 16). (C) Serum Ig- light chain Western
blot  analysis of neonatal MIA  rat (postnatal days 3). (B) and (C) Upper four panels show Western blots of Ig- light chain proteins together with albumin as controls in
serum  of the control and MIA  samples. The Ig- light chain and albumin speciﬁc bands were at 25k and 65k, respectively, on SDS-PAGE gel. The Ig- light chain levels were
normalized by albumin of the MIA  sera. Dot charts indicate the normalized serum Ig- light chain levels of control- and MIA-rat. Concentration ratios of Ig- light chain to
albumin indexed to control show increase in the serum of both mature- and neonatal-MIA rats. Data are expressed as percentage of the value of the control rats. Asterisks
*  ± SD.
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b*,  *** in the ﬁgures indicate P < 0.01, P < 0.001 respectively. Error bars denote mean
ncrease FLC concentrations in the patient sera. We  thereby mea-
ured FLCs and pro-inﬂammatory cytokines in serum samples of
atients with sporadic schizophrenia and healthy control donors
urchased from PrecisionMed, Inc., USA.
Fig. 3A and B shows that both free Ig- light chain (FLC) and
ree Ig- light chain (FLC) concentrations in the patient sera were
igniﬁcantly higher than those in the sera of healthy control. Sum-
ary statistics by Student’s t-test for FLC (t(15) = 2.22, P = 0.041,
ffect size: d = 1.08,  ˛ error probability: 0.05, Power (1−ˇ error
robability): 0.547); and for FLC (t(15) = 2.7, P = 0.016, effect size: = 1.93,  ˛ error probability: 0.05, Power (1−ˇ  error probability):
.959). Fig. 3C shows that FLC-to-FLC ratio (rFLC) of the patient
roup sera and healthy control sera were not signiﬁcantly different
etween the two groups.4. Discussion
The present study showed the following two kinds of experi-
mental data. (1) Reproducible speciﬁc augmentation of Ig- light
chain was  observed in serum proteome of MIA  rat, but pro-
inﬂammatory cytokines in sera were too low to be detected
by our ELISA protocol. The augmentation of Ig- light chain
was also observed in serum of neonatal MIA  rat. Antipsychotic
drug (haloperidol-decanoate) long-acting injection had little effect
on the Ig- light chain level in sera of MIA  rat. (2) FLCs but
not pro-inﬂammatory cytokines were augmented in sporadic
schizophrenia patient sera for research.
Maternal immune activation GD15 to GD21 produce neuronal
and behavioral abnormality in the offspring and maternal immune
68 A. Oh-Nishi et al. / Neuroscience Research 113 (2016) 63–70
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g/l  of healthy and schizophrenia groups. (C) Dot chart of the -to- FLC ratio (rFL
nd  N = 9, respectively. Asterisks “*” stand for P < 0.05. Horizontal lines and error ba
ctivation induced by Poly I:C doses ranging from 4 to 20 mg/kg
ed to a number of abnormal behaviors in the offspring at adult-
ood (Bilbo and Schwarz, 2009; Macedo et al., 2012; Meyer et al.,
005; Ozawa et al., 2006; Smith et al., 2007; Wolff and Bilkey, 2008;
uckerman et al., 2003a, 2003b; Zuckerman and Weiner, 2005). In
he present study, Poly I:C potassium salt (4 mg/kg) dissolved in
aline was injected into the pregnant Wistar rats intraperitoneally
I.P.) daily for 4 consecutive days from GD15 to GD18. The injection
rotocol in the present study is therefore different from those used
n previous MIA  rat model studies (Dickerson et al., 2010; Wolff
nd Bilkey, 2008; Zuckerman et al., 2003a, 2003b; Zuckerman and
einer, 2005), but our injection protocol seems to be adequate hav-
ng produced neuronal and behavioral abnormality in the Wistar rat
ffspring born from Poly I:C-injected rats similar to the one seen in
nother MIA  rodent model (Oh-Nishi et al., 2011).
In our study, we found more than two-fold augmentation of Ig-
 light chain in serum proteome of the MIA  model rat. It should
e remembered that we had observed Ig light chains in rat sera
ith no distinction whether they were free or not, but it is not
nreasonable to hypothesize that the augmentation of Ig- light
hain was caused by immune B-cell activation in the rat, accom-
anied by elevation of polyclonal FLCs, ending up with abnormal
 cell responses. A recent work showed that MIA  leads to perma-
ently hyper-responsive CD4+ T cells in offspring of mice, and the
ypersensitive immune system in offspring and also behavioral
bnormality of rodents could in part be normalized by bone marrow
ransplant (Hsiao et al., 2012).
Free Ig- light chain have long been considered simply to be
pillover remnants of the regular Ig production in B cells, but
ctually induce mast-cell-driven hypersensitivity (Redegeld and
ijkamp, 2003; Redegeld et al., 2002). Although the causal rela-
ionship between augmentation of serum Ig- light chain and
ehavioral dysfunction in the MIA  animal model is not yet known,
e can at least infer the implication of the augmentation of Ig-patient groups. (A) Dot chart of FLC concentrations in mg/l, and (B) that of FLC in
he two groups. Numbers of sera samples of patients and healthy controls are N = 8
ote mean ± SD.
light chain in the MIA  rat model with reference to the behavior-
modulating role of mast cell activation, which extends beyond
several behaviors in rodents. Pretreatment of rats with mast cell
degranulator inhibitor before a restraint stress protected them from
exhibiting social behavior post stress (Manchanda et al., 2011), sug-
gesting that mast cell activation modulates emotional and social
behaviors.
Relative proportions of Ig- and Ig- light chains vary con-
siderably with species (Davies et al., 1975) and rFLC is therefore
species-dependent. Ig- light chains level are much more than Ig-
 light chains in rodent serum (Davies et al., 1975). rFLC in rodent
serum seems not to be useful for immunological indicator. As both
Ig- and Ig- light chains are richly present in human serum, rFLC
in human sera is used for clinical diagnostics index (Katzmann et al.,
2002). The reference range of rFLC for human sera is 0.26–1.65
(Katzmann et al., 2002). Outlier rFLC values are observed with an
elevation in at least one of FLC or FLC by clonal disorders in
plasma cells such as MGUS (monoclonal gammopathy of undeter-
mined signiﬁcance) (Dispenzieri et al., 2012). The mean rFLC value
of sera of the patients with schizophrenia was  0.926 in the present
study, which is in the reference range.
Serum IL-6 increase has been reported in patients with
schizophrenia (Potvin et al., 2008), but IL-6 in MIA  rat sera was
undetectable by the ELISA protocol. MIA  leads to permanently
hypersensitive CD4+ T-cells in offspring, which indicates a chronic
pro-inﬂammatory phenotype (Hsiao et al., 2012), and hypersen-
sitive CD4+ T-cells release more IL-6 after in vitro stimulation. If
MIA  rats raised in the SPF (speciﬁc pathogen-free) laboratory of
our institute had been exposed to a lot of various immune stimu-
lators (i.e., virus, bacteria, etc.), augmentation of IL-6 in the serum
would have been detected.
There have been a number of studies on schizophrenia-
linked genomic variations. Genome-wide association studies have
revealed that the major histocompatibility complex (MHC) region
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nal  antibodies to infectious agents and risk for non-affective psychoses in the
offspring – a matched case-control study. Schizophr. Res. 140, 25–30.A. Oh-Nishi et al. / Neurosci
n the short arm of chromosome 6 is involved in schizophre-
ia susceptibility (Irish Schizophrenia Genomics Consortium and
he Wellcome Trust Case Control Consortium 2, 2012; Corvin and
orris, 2013). Considering the multi-role of the MHC  region in
mmunity, its involvement in schizophrenia susceptibility is not
urprising. Our ﬁnding of FLC elevation as a biomarker candidate
f the disease also suggests that patients’ immune systems are
nvolved in the disease. As Ig- light chain gene transcription is
nhanced by NF-B in B cells (Kaileh and Sen, 2012), NF-B-related
ene alterations in patients with schizophrenia (Begni et al., 2003;
ashimoto et al., 2011; Liou et al., 2012) might be related to the
levation of FLCs.
Recently it is suggested that mild chronic inﬂammation
ould cause multiple endophenotypes similar to patients with
chizophrenia. Deﬁciency of schnurri-2 induced mild chronic
nﬂammation to produce neuronal and behavioral phenotypes
elated schizophrenia (Choi et al., 2015; Takao et al., 2013). Our MIA
ats reveal parvalbumin positive interneuronal loss in medial pre-
rontal cortex and reduction of pre-pulse inhibition (Oh-Nishi et al.,
011) which is similar to schnurri-2 knockout mouse. Schnurri-
 knockout mouse reveal constitutive NF-B activation in CD4+
ell (Kimura et al., 2007). The ﬁndings indicate that NF-B related
ild chronic inﬂammation might cause neuronal and behavioral
eﬁcits. Augmentation of Ig- light chain in the MIA  rat sera
hown in the present paper might be re-examined in the future
n the context of mild chronic inﬂammation caused by NF-B
ctivation.
Our study has four limitations. First comes from 2-DE-based pro-
eomics, i.e., not all high-molecular-mass and/or low-abundance
roteins and low molecular-mass peptides in sera of MIA rats are
eparated by and detected in 2-DE gels. In the context of our present
tudy, immunological factors other than FLCs would naturally be
xpected to be biomarker candidates, but 2-DE-based proteomics
hat we had used made it difﬁcult for us to detect such impor-
ant immunological factors as cytokines and chemokines. Second
s the number of the rodent model sera used in the present study;
e compared 2-DE gel images of three MIA  and three control rat
era for exploring biomarker candidate proteins, and we identi-
ed Ig- in the MIA  rat sera. Although the number of comparisons
as limited, the rodent models being homogeneous genetically
nd having been raised in a controlled environment, we success-
ully detected variations of Ig- abundance in six 2-DE images of
he MIA  and control rat sera. Third is the uncontrollable hetero-
eneity of the human sera we used; the donors are heterogeneous
n their life and medical histories, such as smoking, antipsychotic
gent treatments, duration of medication and weight gain poten-
ially, which would inﬂuence their immune systems (Hinze-Selch
nd Pollmacher, 2001; Pollmacher et al., 1997). Moreover, it was
ot known whether or not the patient donors had experienced
aternal infection during their fetal lives. Despite of the donor
eterogeneities noted in the above we observed augmentation of
erum FLCs in the sera of patients with sporadic schizophrenia.
hose donor heterogeneities must be taken into consideration in
ny clinical study in the future. Fourth is the speciﬁcity of FLCs for
he MIA-associated neurodevelopmental disorder. Augmentation
f serum FLCs itself occurs under various conditions, such as chronic
nﬂammatory diseases, oncological and B-cell related disorders, to
ame a few, and is not speciﬁc enough for the MIA-associated
eurodevelopmenatal disorders. Our rodent model experiment
ndicates that MIA-associated neurodevelopmental disorders have
haracteristics different from chronic inﬂammatory diseases
i.e., augmentation of serum FLCs but not pro-inﬂammatory
ytokines). In this context, the combined assay of serum FLCs
nd other immunological factors would provide higher speciﬁcity
or MIA  associated neurodevelopmental disorders than serum FLC
lone.esearch 113 (2016) 63–70 69
5. Conclusion
We found a novel serologic biomarker candidate for MIA associ-
ated neurodevelopmental disorders in MIA  rat model. We  propose
a future research direction in which combined assay of serum FLCs
and other immunological factors would provide a clue toward real-
ization of a serodiagnostic test for neurodevelopmental disorders
with MIA  background. Our proposal surely needs to be scrutinized
more closely than examined in the present study, but it is still wor-
thy of being validated for our developing novel serodiagnostic tools,
preventive methods and treatment strategy of the organic mental
disorders with MIA  background.
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